|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Perjeta
gptkb:Herceptin
|
|
gptkbp:activities
|
HE R2 receptor blockade
|
|
gptkbp:appointed_by
|
intravenous infusion
chemotherapy
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:2012
gptkb:FDA
gptkb:United_States
|
|
gptkbp:can_be_used_with
|
gptkb:trastuzumab
|
|
gptkbp:clinical_trial
|
gptkb:APHINITY_trial
gptkb:CLEOPATRA_trial
gptkb:NEOSPHERE_trial
Phase III
adjuvant therapy
neoadjuvant therapy
metastatic breast cancer
|
|
gptkbp:combatants
|
high
|
|
gptkbp:contraindication
|
pregnancy
lactation
hypersensitivity to pertuzumab
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
loading dose followed by maintenance dose
|
|
gptkbp:frequency
|
every 3 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pertuzumab
|
|
gptkbp:indication
|
HE R2-positive breast cancer
|
|
gptkbp:ingredients
|
C6460 H9932 N1716 O1980 S44
|
|
gptkbp:interacts_with
|
other HE R2-targeted therapies
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
cardiac function
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:manager
|
IV
|
|
gptkbp:marketed_as
|
gptkb:Perjeta
|
|
gptkbp:pharmacokinetics
|
long half-life
inhibition of HE R2 signaling
|
|
gptkbp:produced_by
|
recombinant DNA technology
|
|
gptkbp:provides_information_on
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:research
|
other cancers
|
|
gptkbp:research_focus
|
combination therapies
biomarker studies
resistance mechanisms
patient selection
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
peripheral neuropathy
thrombocytopenia
infusion reactions
neutropenia
hypersensitivity reactions
cardiac dysfunction
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
HE R2
|
|
gptkbp:treatment
|
with trastuzumab and docetaxel
|
|
gptkbp:type
|
humanized monoclonal antibody
|
|
gptkbp:website
|
IV site
|
|
gptkbp:weight
|
148 k Da
|